658 related articles for article (PubMed ID: 29914800)
1. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.
Mazur NI; Higgins D; Nunes MC; Melero JA; Langedijk AC; Horsley N; Buchholz UJ; Openshaw PJ; McLellan JS; Englund JA; Mejias A; Karron RA; Simões EA; Knezevic I; Ramilo O; Piedra PA; Chu HY; Falsey AR; Nair H; Kragten-Tabatabaie L; Greenough A; Baraldi E; Papadopoulos NG; Vekemans J; Polack FP; Powell M; Satav A; Walsh EE; Stein RT; Graham BS; Bont LJ;
Lancet Infect Dis; 2018 Oct; 18(10):e295-e311. PubMed ID: 29914800
[TBL] [Abstract][Full Text] [Related]
2. The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.
Frenkel LD; Gaur S; Bellanti JA
Allergy Asthma Proc; 2023 Jul; 44(4):220-228. PubMed ID: 37236777
[No Abstract] [Full Text] [Related]
3. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
5. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
[TBL] [Abstract][Full Text] [Related]
6. Development of mRNA vaccines against respiratory syncytial virus (RSV).
Qiu X; Xu S; Lu Y; Luo Z; Yan Y; Wang C; Ji J
Cytokine Growth Factor Rev; 2022 Dec; 68():37-53. PubMed ID: 36280532
[TBL] [Abstract][Full Text] [Related]
7. New preventive strategies for respiratory syncytial virus infection in children.
Glowinski R; Mejias A; Ramilo O
Curr Opin Virol; 2021 Dec; 51():216-223. PubMed ID: 34781106
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.
Esposito S; Di Pietro G
Future Microbiol; 2016 Oct; 11():1479-1490. PubMed ID: 27750448
[TBL] [Abstract][Full Text] [Related]
9. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.
Modjarrad K; Giersing B; Kaslow DC; Smith PG; Moorthy VS;
Vaccine; 2016 Jan; 34(2):190-197. PubMed ID: 26100926
[TBL] [Abstract][Full Text] [Related]
10. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
12. Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.
Cayatte C; Snell Bennett A; Rajani GM; Hostetler L; Maynard SK; Lazzaro M; McTamney P; Ren K; O'Day T; McCarthy MP; Schneider-Ohrum K
PLoS One; 2017; 12(11):e0188708. PubMed ID: 29182682
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus infection and novel interventions.
Langedijk AC; Bont LJ
Nat Rev Microbiol; 2023 Nov; 21(11):734-749. PubMed ID: 37438492
[TBL] [Abstract][Full Text] [Related]
14. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
[TBL] [Abstract][Full Text] [Related]
15. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey I; Saelens X
Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
[No Abstract] [Full Text] [Related]
16. Vaccines against respiratory syncytial virus: The time has finally come.
Graham BS
Vaccine; 2016 Jun; 34(30):3535-41. PubMed ID: 27182820
[TBL] [Abstract][Full Text] [Related]
17. Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.
Kotomina T; Isakova-Sivak I; Matyushenko V; Kim KH; Lee Y; Jung YJ; Kang SM; Rudenko L
Antiviral Res; 2019 Aug; 168():9-17. PubMed ID: 31075351
[TBL] [Abstract][Full Text] [Related]
18. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
19. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
[TBL] [Abstract][Full Text] [Related]
20. Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.
Zhang L; Durr E; Galli JD; Cosmi S; Cejas PJ; Luo B; Touch S; Parmet P; Fridman A; Espeseth AS; Bett AJ
Vaccine; 2018 Dec; 36(52):8119-8130. PubMed ID: 30340881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
